The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KRRO | -88.72% | -99.55% | -66.02% | -62% |
| S&P | +13% | +86.41% | +13.26% | +55% |
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.09M | 0.0% |
| Gross Profit | -$0.11M | 87.3% |
| Gross Margin | -10.09% | 0.0% |
| Market Cap | $449.73M | 44.7% |
| Market Cap / Employee | $5.17M | 56.4% |
| Employees | 87 | 0.0% |
| Net Income | -$18.06M | 14.0% |
| EBITDA | -$18.04M | 19.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $25.16M | -61.3% |
| Accounts Receivable | $0.82M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $41.52M | -0.6% |
| Short Term Debt | $3.15M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -43.65% | 26.4% |
| Return On Invested Capital | -46.08% | -6.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$17.35M | 17.3% |
| Operating Free Cash Flow | -$17.18M | -6.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.97 | 1.02 | 0.84 | 3.91 | 149.55% |
| Price to Sales | 157.20 | 33.89 | 18.67 | 61.02 | - |
| Price to Tangible Book Value | 1.97 | 1.02 | 0.84 | 3.91 | 149.55% |
| Enterprise Value to EBITDA | -12.65 | -3.93 | -2.48 | -22.23 | 133.03% |
| Return on Equity | -50.6% | -60.2% | -58.3% | -63.5% | -32.43% |
| Total Debt | $44.77M | $45.19M | $44.63M | $44.67M | 6.90% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
